Biotechs AIM for alternative financing: London's lesser-known stock exchange offers the possibility of money for hungry biotechs
Article Abstract:
US biotech companies are raising money through IPOs on London's Alternative Investment Market, (AIM) which was set up to create a financial marketplace where small and speculative companies could find backing since they find it difficult to find finance despite having very good technology. While AIM offers biotechs the potential of cash and few regulatory strings, it still has its risks since analyst coverage of AIM stocks is light and past bad experiences.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Ramping up tech transfer
Article Abstract:
The measures that are being taken to use the inventions of the universities and research centers of the Greater Philadelphia region in developing its biotech and pharmaceutical businesses are discussed.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
Ben Franklin Technology Partners of Southeastern Pennsylvania
Article Abstract:
The Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) is a regional nonprofit organization, which provides expertise and capital to other companies for their growth.
Publication Name: The Scientist
Subject: Biological sciences
ISSN: 0890-3670
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Separating nurture from nature in estimating heritability. A multivariate model for ordinal trait analysis. A penalized maximum likelihood method for estimating epistatic effects of QTL
- Abstracts: A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Getting downstream without a Raft
- Abstracts: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development
- Abstracts: Reduction of soluble and insoluble iron forms by membrane fractions of Shewanella oneidensis grown under aerobic and anaerobic conditions
- Abstracts: Merck's fall from grace. Getting together on genomics. Daniel Skovronsky: a physician-scientist and business leader